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Stress responseAbstract Background and objective: In this study we evaluated oral ivabradine (a relatively new
heart rate lowering agent) versus oral propranolol (a classic commonly used beta-blocker) in achiev-
ing a hemodynamic stability and controlling possible changes in blood glucose level due to stress
response in microlaryngoscopic surgeries.
Methods: A total of 50 American Society of Anesthesiologists (ASA) 1,2 patients scheduled for
microlaryngoscopic surgeries were included in this prospective, randomized controlled double blind
study. They were given either oral ivabradine (5 mg tablet) group I or oral propranolol (10 mg
tablet) group P in the evening before the operation and 1 h before the induction of anesthesia.
Hemodynamic variables (systolic, diastolic, mean blood pressure and heart rate) and blood glucose
level were recorded perioperatively.
Results: The changes in blood pressure and heart rate in both groups were mild after intubation,
laryngoscope fixation for surgery and extubation but these changes in ivabradine group were signif-
icantly less than the changes in propranolol group (P< 0.05). No significant difference (P> 0.05)
was found between both groups in blood glucose level perioperatively. No statistically significant
complications were observed in both groups.
Conclusion: Premedication with 5 mg of oral ivabradine or 10 mg of oral propranolol before
microlaryngoscopic surgeries was effective in achieving a good degree of hemodynamic stability
but ivabradine was more effective. Both drugs didn’t show an obvious effect on blood glucose level
perioperatively. No complications were recorded.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., Cairo,
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There has been an increase in laryngoscopic surgeries which
may be due to the marked increase in laryngeal tumours in
recent years. Laryngeal tumours may be benign or malignant
including vocal nodules, vocal polyps, vocal fold cysts and
papilomas. Poor vocal hygiene and smoking are often consid-
ered to be risk factors. In some cases, in order to obtain an
accurate diagnosis of a vocal fold lesion it is necessary to per-
form laryngoscopy, which also allows for proper dysphonia
treatment through microsurgery [1]. Manipulation of the lar-
ynx such as laryngoscopy and tracheal intubation is associated
with hemodynamic response consisting of an increase in heart
rate, arterial blood pressure, myocardial oxygen demand and
induction of dysrhythmias. In microlaryngoscopic surgery,
these responses are more intense [2]. In patients with coronary
artery disease, hypertension or cerebrovascular disease, these
changes may precipitate myocardial ischemia, myocardial
infarction and cerebral hemorrhage [3,4]. Laryngoscopy and
surgical procedures also induce complex stress responses,
manifested by metabolic, neurohumoral, and immunological
changes. Hyperglycemia is a feature of this metabolic
response [5].
The choices of premedication and anesthetic techniques are
able to influence the neurohormonal stress response by modu-
lating the pathophysiological pathways [6–8].
Ivabradine is a very unique drug. It is a highly selective
inhibitor of ‘If’ channels (funny current or funny channels or
pacemaker current). It is useful in patients with angina pec-
toris, coronary artery disease and heart failure. Ivabradine is
quite different from a beta blocker as it reduces the heart rate
without jeopardizing hemodynamics in unhealthy, compro-
mised patients [9]. The drug can be used not only in hyperten-
sive patients but also in normotensive patients, diabetic
patients and patients with bronchial asthma where beta block-
ers are contraindicated [10].
The rationale of the present study is to minimize stress
response in microlaryngoscopic surgeries. We evaluated the
effect of oral ivabradine on the hemodynamics and blood glu-
cose level in these surgeries under general anesthesia compared
with a commonly used beta-blocker propranolol given orally.
2. Patients and methods
This was a prospective, randomized, double blind, compara-
tive clinical study performed in Ain Shams University Hospi-
tals from March 2015 till October 2015. After getting
approval from the institutional ethical committee, an informed
consent was taken from every patient enrolled in the study.
Fifty patients aged P25 to 660 years, planned for elective
microlaryngoscopic surgeries were included in this study. The
exclusion criteria included the following: ASA physical status
>2, taking beta-blockers or sedatives or antihypertensives,
inability to communicate with the patient due to any reason,
patients with history of respiratory troubles or diabetes melli-
tus and those with anticipated difficult airway. Exclusion crite-
ria also included patients with history of chest pain,
palpitations, syncope or with baseline heart rate <60 beats
per minute, baseline systolic blood pressure <100 mm Hg
and those with ECG abnormalities. Routine preoperative
investigations were done for all patients.The patients were randomly allocated by simple randomiza-
tion into two groups (having 25 patients in each group):
GROUP I: who received oral ivabradine, 5 mg one tablet at
8.00 pm in the evening before the day of the surgery and one
5 mg tablet one hour before the induction of anesthesia.
GROUP P: who received oral propranolol, 10 mg one
tablet at 8:00 pm in the evening before the day of the surgery
and one 10 mg tablet one hour before the induction of
anesthesia.
Randomization sequence was concealed in sealed envelopes
performed by the help of an independent personnel. An appro-
priate code number was assigned to each patient, with an allo-
cation ratio of 1:1. The test medications were given to patients
by an attending anesthesiologist who was not involved in
patient care or data collection. Data collection was carried
out by investigators in a double-blind manner. All patients,
investigators and anesthesiologists were blinded to the admin-
istered test drugs.
No hypnotic medication was given on the evening before
surgery. Patients were premedicated with glycopyrrolate
0.02 mg/kg i.v. and ondansetron 4 mg i.v. in the preoperative
room. Upon arrival in the operating room, monitors were
attached to the patients and heart rate, NIBP, oxygen satura-
tion, temperature, end tidal CO2, and ECG were recorded.
After pre-oxygenation with O2 100% for 3 min, anesthesia
was induced with a standard anesthetic protocol using
midazolam 0.03 mg/kg, fentanyl 1 lg/kg, thiopentone sodium
3–5 mg/kg, and tracheal intubation was facilitated by
atracurium 0.5 mg/kg intravenously. Lungs were mechanically
ventilated with O2 50% and anesthesia was maintained with
isoflurane 0.8% and atracurium 0.1 mg/kg every 25 min.
Ventilation was adjusted to maintain normocapnia (end-tidal
carbon dioxide [EtCO2] 40 ± 5 mmHg). After tracheal intuba-
tion with a cuffed endotracheal tube (size 5.0–5.5), the surgeon
fixed the laryngoscope and the procedure started. During
surgery, Ringer’s lactate solution was administered in
maintenance dose as per Holliday-Segar formula. The anesthe-
siologists were ready to manage any hypotension
(MAP< 20% preoperative) with a fluid bolus of normal
saline 250–300 ml and ephedrine 15 mg i.v if needed. Any inci-
dence of bradycardia (HR< 50/min) was ready to be treated
with atropine 0.7 mg i.v.
At the end of the surgery, residual neuromuscular block
was reversed by the injection of neostigmine 0.05 mg/kg and
glycopyrrolate 0.02 mg/kg i.v. and the patients were extubated
when respiration was sufficient, and they were able to obey
commands.
Patients were transferred to the postanesthesia care unit
(PACU) where they were monitored for at least 3 h for any evi-
dence of complications or adverse events. Systolic (SBP), dias-
tolic (DBP), mean (MBP) arterial blood pressures and heart
rate (HR) were recorded at the following points of time:
(1) Baseline in the evening before the day of operation
immediately before taking the test drugs.
(2) Immediately before induction of anesthesia.
(3) One minute after intubation.
(4) Three minutes after intubation.
(5) Five minutes after laryngoscope fixation.
(6) Fifteen minutes after laryngoscope fixation.
(7) One minute after extubation.
(8) Three minutes after extubation.
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Optium Xceed) for blood glucose level at the following points
of time:
(1) Baseline.
(2) Immediately before induction of anesthesia.
(3) Ten minutes after intubation.
(4) One hour after extubation.
The results obtained in the study are presented in tabulated
manner.
The primary outcomes of our study were as follows: systolic
blood pressure, diastolic blood pressure, mean blood pressure
and heart rate. The secondary outcome was blood glucose level
and any possible side effects of the 2 drugs.
2.1. Statistics
Statistical presentation and analysis of the present study were
conducted, using the mean, standard deviation, Chi-square,
paired t-test and unpaired t-test by SPSS V.20. Unpaired Stu-
dent T-test was used to compare between the two groups in
quantitative data. Fisher’s exact test and Yates’ corrected
chi-square are computed for 2  2 tables.
2.2. Sample size
The sample size was calculated using Epicalc 2000 software
depending on the results from previous studies 4 and 11 with
the following parameters:
Type I error (a) = 5% with confidence level 95% and
power of study 90% (power of test) with type error II 10%
(Beta) with expected difference of 0.32. The minimal sample
size was 23 in each group. A total of 25 patients in each group
were included to compensate for possible dropouts. Corre-
sponding P was computed. P< 0.05 was considered as statis-
tically significant.
2.3. Significant level
Non-significant >0.05, significant <0.05*, highly significant
<0.001*.
3. Results
Sixty patients were primarily enrolled in the study. Ten
patients were then excluded as they didn’t meet the inclusion
criteria (Fig. 1).
Fifty patients were then finally included in the study and
divided into two equal groups. There were no significant differ-
ences between the two groups as regards demographic data
such as age, sex, weight and ASA grade (Table 1).
Baseline and preinduction data (SBP, DBP, MBP and HR)
were compared between the two groups of patients and no sig-
nificant difference was found. Systolic arterial pressure, dias-
tolic blood pressure, mean blood pressure and heart rate
increased slightly after intubation in both groups.
However in group I, the increase in these parameters was
less than in group P and it was statistically significant. SBP,
DBP, MBP and HR increased slightly again after laryngoscopefixation for surgery and also in group I the increase was less
than in group P and it was statistically significant. After extu-
bation, values showed that the rise in group I in such param-
eters was also less than in group P and it was also
statistically significant (Tables 2–5).
Random blood glucose level (RBG) was analyzed in the
patients. Preinduction values were less than baseline values
in the two groups but that were not statistically significant.
Slight increase in blood glucose level was noticed in both
groups shortly after intubation and after extubation but that
was also not statistically significant (Fig. 2).
No incidence of possible side effects (bradycardia, hypoten-
sion, bronchospasm, etc.) was recorded perioperatively.
4. Discussion
In this study, we compared between the use of oral ivabradine
to oral propranolol in patients undergoing laryngoscopic surg-
eries under general anesthesia to evaluate the efficacy of both
drugs in attenuating the rise in blood pressure and heart rate
occurring after laryngoscopy and intubation and to check
whether they have an effect on blood glucose level
perioperatively.
Stress response is a neuroendocrine complex occurring due
to anesthesia and surgery. Even with stable anesthesia, laryn-
goscopy alone without intubation can cause a supraglottic
stimulus. This stimulus leads to an increase in BP which is
due to norepinephrine, and increase in HR which is due to epi-
nephrine discharge. Placing the endotracheal tube can cause an
infraglottic stimulus. In this situation, an extra cardiovascular
response and catecholamine discharge occur. Stress response
increases at this stage and both SBP and DBP in addition to
HR measurements increase by up to 36–40% in contrast to
control levels and hyperglycemia can be a feature of this
response [11,12]. Bessey et al. [13] have suggested that
increased circulating concentrations of catecholamines, gluca-
gon, and cortisol can evoke the changes in carbohydrate meta-
bolism, occurring immediately after trauma.
In microlaryngoscopic surgery, these responses are more
intense than in laryngoscopy for endotracheal intubation
because the laryngoscope is introduced into the upper airways
for 15–20 min compared to 15–30 s in tracheal intubation [2].
Tachycardia along with hypertension increases ischemia
risk in patients with coronary artery disease. The increase in
the plasma concentration of catecholamines may provoke
myocardial ischemia and cerebral hemorrhage [8].
As controlling stress response is so important to the anes-
thesiologist, many strategies to circumvent this pressor
response were tried such as minimizing the duration of laryn-
goscopy, IV narcotics, topical lidocaine, vasodilators, beta-
blockers, oral gabapentin, oral clonidine and calcium channel
blockers [2,3,11,14].
Also some studies were performed in microlaryngeal surg-
eries specifically, for example, Bharti et al. [15] compared the
hemodynamic changes and emergence characteristics of
sevoflurane versus propofol anesthesia for microlaryngeal sur-
gery. They found that sevoflurane was better than propofol in
intraoperative cardiovascular stability without increasing
recovery time. Boussofara et al. [2] evaluated the effect of
esmolol on cardiovascular changes during microlaryngeal sur-
gery. They showed that the infusion of esmolol can prevent
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Figure 1 The study flow diagram.
506 A.N. Ibrahim, R.Y. Atallahcardiovascular changes after microlaryngeal surgery. Ayatol-
lahi et al. [16] showed that 800 mg gabapentin 90 min before
the microlaryngoscopy can attenuate increasing diastolic
blood pressure and mean arterial blood pressure in the first
15 min after this procedure, but has no effect on systolic blood
pressure or heart rate.
Propranolol is non-selective ß blocker. ß1 effect decreases
heart rate and ß2 effect on skeletal muscle vascular bed may
help in decreasing after load of heart. It may cause bradycar-dia, AV dissociation and hypoglycemia. Bronchospasm,
congestive heart failure and drowsiness can occur even with
low doses. Propranolol can be given orally and intravenously
[17].
Some studies evaluated the efficacy of beta-blockers
including propranolol in decreasing stress response due to
laryngoscopy [18–21].
Maharjan [21] showed that 1 mg propranolol i.v. is superior
to 0.5 mg in controlling hemodynamics after laryngoscopy and
50
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Figure 2 Changes in RBG.
Table 1 Demographic data.
Groups Age T-test
Range Mean ± SD t P-value
Group I 38.0–55.0 45.08 ± 4.98 0.305 0.762
Group P 38.0–57.0 45.52 ± 5.23
Sex Groups
Group I Group P Total
N % N % N %
Female 3 12.0 2 8.0 5 10.0
Male 22 88.0 23 92.0 45 90.0
25 100.0 25 100.0 50 100.0
T-test 0.222
p-Value 0.637
Groups Weight T-test
Range Mean ± SD t P-value
Group I 60.0–90.0 70.64 ± 8.31 1.498 0.141
Group P 60.0–90.0 74.04 ± 7.73
ASA Groups
Group I Group P Total
N % N % N %
I 19 76.0 17 68.0 36 72.0
II 6 24.0 8 32.0 14 28.0
Total 25 100.0 25 100.0 50 100.0
Chi-square X2 0.397
P-value 0.529
Ivabradine versus propranolol 507intubation without significant bradycardia in postoperative
period.
Ivabradine is a relatively new HR lowering agent that not
only decreases myocardial oxygen demand as assessed by therate pressure product, to the same extent as propranolol, but
also acts without any evidence of a depressant effect on cardiac
function [22]. If is thought to be one of the most important cur-
rents in pacemaking in the sino-atrial node [23]. Animal studies
Table 2 Changes in SBP.
SBP Groups
Group I Group P T-test
Mean ± SD Mean ± SD t P-value
Baseline 119.80 ± 2.16 117.70 ± 2.08 0.000 1.000
Before induction 122.28 ± 2.32 122.42 ± 2.16 0.000 1.000
1 min after intubation 123.24 ± 2.88 127.51 ± 2.75 2.172 0.034*
3 min after intubation 118.20 ± 2.63 122.30 ± 2.45 2.643 0.011*
5 min after laryngoscope fixation 121.68 ± 2.79 127.57 ± 2.66 4.034 <0.001*
15 min after laryngoscope fixation 122.36 ± 2.64 123.36 ± 2.39 2.808 0.007*
1 min after extubation 121.00 ± 2.77 122.72 ± 2.94 5.842 <0.001*
3 min after extubation 117.16 ± 3.12 121.00 ± 3.27 4.252 <0.001*
Paired t-test
t P-value t P-value
Baseline & before induction 16.098 <0.001* 16.098 <0.001*
Baseline & 1 min after intubation 18.082 <0.001* 18.082 <0.001*
Baseline & 3 min after intubation 7.686 <0.001* 7.686 <0.001*
Baseline & 5 min after laryngoscope fixation 3.934 0.002* 3.934 0.002*
Baseline & 15 min after laryngoscope fixation 19.613 <0.001* 19.613 <0.001*
Baseline & 1 min after extubation 35.393 <0.001* 9.177 <0.001*
Baseline & 3 min after extubation 23.619 <0.001* 11.898 <0.001*
* Statistically significant.
Table 3 Changes in DBP.
DBP Groups
Group I Group P T-test
Mean ± SD Mean ± SD t P-value
Baseline 79.92 ± 1.55 79.44 ± 1.23 1.213 0.231
Before induction 78.80 ± 1.38 78.80 ± 1.15 0.000 1.000
1 min after intubation 80.92 ± 1.71 82.52 ± 1.64 3.385 <0.001*
3 min after intubation 79.20 ± 1.41 81.32 ± 1.18 5.754 <0.001*
5 min after laryngoscope fixation 80.24 ± 1.51 82.96 ± 1.54 6.309 <0.001*
15 min after laryngoscope fixation 80.60 ± 2.40 81.88 ± 1.39 2.308 0.025*
1 min after extubation 80.44 ± 1.71 81.68 ± 1.25 2.928 0.005*
3 min after extubation 79.04 ± 1.83 81.04 ± 1.34 3.532 <0.001*
Paired t-test
t P-value t P-value
Baseline & before induction 7.716 <0.001* 6.532 <0.001*
Baseline & 1 min after intubation 5.477 <0.001* 14.842 <0.001*
Baseline & 3 min after intubation 3.845 <0.001* 7.608 <0.001*
Baseline & 5 min after laryngoscope fixation 2.248 0.005* 18.283 <0.001*
Baseline & 15 min after laryngoscope fixation 2.240 0.035* 12.696 <0.001*
Baseline & 1 min after extubation 2.029 0.017* 9.925 <0.001*
Baseline & 3 min after extubation 3.427 <0.001* 12.394 <0.001*
* Statistically significant.
508 A.N. Ibrahim, R.Y. Atallahindicate that ivabradine is a selective and specific inhibitor of
If, and has few effects other than to slow the rate of diastolic
depolarization and hence reduces HR. This specificity may
explain the absence of significant negative inotropic actions
of ivabradine observed in entire animal studies [24–26].
Ivabradine has been very useful in controlling the hemody-
namics particularly the heart rate in all types of patients
especially in patients where beta blockers are contraindicated
such as asthmatics and diabetics. It can be given orally and
intravenously [22].Some studies were done to evaluate the effectiveness of ivab-
radine in cardiac patients. Fox et al. [27] showed that in coro-
nary patients with a heart rate more than 70 bpm, ivabradine
significantly reduces the risk of myocardial infarction by 36%.
In a study done by Swedberg et al. [28] administration of
ivabradine to heart failure patients significantly reduced the
risk of death from heart failure and hospitalization for heart
failure by 26%.
Raghuram et al. [29] evaluated the efficacy of oral ivabra-
dine to attenuate the hemodynamic responses after intubation.
Table 4 Changes in MBP.
MBP Groups
Group I Group P T-test
Mean ± SD Mean ± SD t P-value
Baseline 92.77 ± 1.00 92.22 ± 1.24 1.726 0.090
Before induction 91.44 ± 1.00 91.20 ± 1.08 0.814 0.420
1 min after intubation 93.52 ± 0.92 94.51 ± 1.12 3.410 <0.001*
3 min after intubation 92.28 ± 0.98 93.44 ± 0.92 4.323 <0.001*
5 min after laryngoscope fixation 93.80 ± 0.87 95.36 ± 0.99 5.913 <0.001*
15 min after laryngoscope fixation 92.38 ± 0.65 93.50 ± 0.83 4.832 <0.001*
1 min after extubation 93.92 ± 0.57 94.70 ± 0.87 3.729 <0.001*
3 min after extubation 91.32 ± 0.90 92.82 ± 0.85 4.853 <0.001*
Paired t-test
t P-value t P-value
Baseline & before induction 10.742 <0.001* 3.874 <0.001*
Baseline & 1 min after intubation 2.761 0.011* 5.914 <0.001*
Baseline & 3 min after intubation 2.874 0.033* 4.423 <0.001*
Baseline & 5 min after laryngoscope fixation 3.881 0.002* 10.553 <0.001*
Baseline & 15 min after laryngoscope fixation 2.395 0.016* 5.335 <0.001*
Baseline & 1 min after extubation 4.446 <0.001* 8.981 <0.001*
Baseline & 3 min after extubation 7.357 <0.001* 2.374 0.020*
* Statistically significant.
Table 5 Changes in HR.
HR Groups
Group I Group P T-test
Mean ± SD Mean ± SD t P-value
Baseline 85.08 ± 2.10 84.88 ± 1.81 0.361 0.719
Before induction 78.82 ± 1.89 79.66 ± 1.37 1.538 0.131
1 min after intubation 76.04 ± 1.40 83.72 ± 1.31 20.054 <0.001*
3 min after intubation 73.68 ± 1.11 81.80 ± 1.15 25.375 <0.001*
5 min after laryngoscope fixation 75.20 ± 1.00 84.72 ± 1.31 28.915 <0.001*
15 min after laryngoscope fixation 74.08 ± 1.19 82.84 ± 1.03 27.888 <0.001*
1 min after extubation 76.56 ± 1.00 85.68 ± 1.46 25.693 <0.001*
3 min after extubation 74.08 ± 1.04 81.84 ± 1.11 25.584 <0.001*
Paired t-test
t P-value t P-value
Baseline & before induction 17.588 <0.001* 6.631 <0.001*
Baseline & 1 min after intubation 16.741 <0.001* 2.790 0.010*
Baseline & 3 min after intubation 23.945 <0.001* 2.723 0.018*
Baseline & 5 min after laryngoscope fixation 19.588 <0.001* 4.564 <0.001*
Baseline & 15 min after laryngoscope fixation 25.017 <0.001* 4.842 <0.001*
Baseline & 1 min after extubation 17.880 <0.001* 7.474 <0.001*
Baseline & 3 min after extubation 23.632 <0.001* 3.510 0.004*
* Statistically significant.
Ivabradine versus propranolol 509They found that ivabradine is an extremely useful drug to pre-
vent abnormal increase in heart rate and blood pressure to a
lesser extent seen during laryngoscopy and endotracheal intu-
bation and recommended its routine use in all patients at risk
for hypertension and tachycardia during laryngoscopy and
endotracheal intubation.
The oral forms of propranolol and ivabradine are well tol-
erated, rapidly and completely absorbed from the gastroin-
testinal tract. The onset of action of the oral forms is within20–30 min, with peak plasma concentration attained within
60–90 min [28,30].
Therefore we preferred to use the oral forms to benefit from
their possible effects as preanesthetic medications. The doses
given to the patients were the lowest starting doses as guided
by the manufacturing pharmaceutical companies.
In our study, blood pressure and heart rate responses to
laryngoscopy, intubation, fixation of laryngoscope and extu-
bation were studied in both groups. Although there were mild
510 A.N. Ibrahim, R.Y. Atallahincreases in blood pressure and heart rate values in both
groups after each stage, both ivabradine and propranolol pro-
vided a good general hemodynamic stability. However, ivabra-
dine was more effective than propranolol with less changes in
blood pressure and heart rate values.
Random blood sugar values were compared between the 2
groups perioperatively, and the preinduction values were
slightly lower than baseline values which was due to fasting
(around 8 h preoperatively). Both drugs didn’t show any sig-
nificant effect on perioperative blood glucose level. We didn’t
notice any possible side effects of either drugs as none of the
patients complained of bradycardia, hypotension nor bron-
chospasm (a common side effect of propranolol).
The limitation of this study is that hemodynamics and
blood glucose levels are not the only variables in the stress
response as many hormones can be affected such as cate-
cholamines, glucagon and cortisone.
In conclusion, both ivabradine and propranolol provide a
good degree of hemodynamic stability in microlaryngoscopic
surgeries but using ivabradine is more effective in addition to
the avoidance of some side effects of beta blockers and the
ability to be used in patients intolerant to beta-blockers. How-
ever, in our study, both drugs didn’t show any obvious effect in
blood glucose level.
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